vor 2 Jahren

Life Sciences Report 2017 / 2018

  • Text
  • Technology
  • Medicine
  • Pharma
  • Berlin
  • Innovative
  • Clinical
  • Sciences
  • Solutions
  • Pharmaceutical
  • Biotech
  • Diagnostics

18 Life

18 Life Sciences Report – Drug Discovery and Development Drug Discovery and Development With specialized biotech companies, global players in the pharmaceutical sector, and a diverse research and clinical landscape the German capital region is a driver for innovative drug discovery and development. Strong networks also offer plenty of opportunities for collaboration along the entire value chain. Outstanding opportunities for cooperation with renowned universities, research institutions, and biotechnology companies ensure excellent prospects for innovative and forward-thinking projects in drug discovery and development. Currently, there are approximately 30 pharmaceutical companies in the capital region with more than 10,000 employees, including global groups such as Bayer, Berlin- Chemie, Pfizer, Sanofi and Takeda. They are joined by over 20 mid-sized pharmaceutical companies. The industry benefits from an excellent scientific environment, the clinical research landscape, proximity to healthcare decision-makers, and highly trained specialists with international backgrounds. With almost 230 companies, the German capital region is also one of the top locations in Europe for biotechnology. Biotech and pharmaceutical industry combine their strengths in a strong network for cooperations on new therapy concepts. The innovative force of the pharmaceutical industry pays off in two different ways for the Berlin-Brandenburg metropolitan region: It ensures patients first-class healthcare, while facilitating economic growth with future-oriented jobs for the region. Clinical studies According to an assessment by public study index by the Verband der forschenden Pharmaunternehmen (vfa), except for the USA there is no other country in the world where so many drug studies are launched as in Germany. The national pharmaceutical industry is number one in the world for studying auto-immune disorders. This means that, with participation in 532 studies launched last year, Germany ranks above Great Britain (499), Canada (463), Spain (384) and France (336). The United States tops the rankings with 2,306 studies. Most studies in Germany are launched in Berlin. Medical institutions such as Charité - Universitätsmedizin there took part in a total of 201 studies. Biotech drug development Around 20 of the roughly 230 biotechnology companies focus on research and development of new active ingredients. Over the last few decades, these companies have made promising progress on both commercial and technological fronts. The following section will provide some examples to better illustrate this point. © All rights reserved / Sebastian Bolesch Takeda plant Oranienburg - excellence center for solid dosage forms, which are exported to more than 100 countries.

Life Sciences Report – Drug Discovery and Development 19 © Bayer “For over 120 years, Bayer has been researching and developing innovative medications and new therapeutic approaches that help make a difference to people’s lives. To help accelerating pharmaceutical innovations, we collaborate with a number of partners from academia and the biotech industry who contribute specialized knowledge and cutting-edge technologies. These co-operations form one of the pillars of Bayer’s innovation strategy. Berlin traditionally holds a central role within our research network. The Berlin research and development network provides excellent interdisciplinary research opportunities and co-operations particularly for application and implementation-oriented collaboration such as the interaction with universities and hospitals in Berlin in the area of clinical research.” Hans Lindner Head of External Innovation & Alliances at Bayer Myelo Therapeutics is currently being investigated in a randomized, double-blind, placebo-controlled, paralleldesign, multicenter study in Germany to assess its efficacy and safety in reducing Chemotherapy-induced Neutropenia (CIN) in patients receiving adjuvant or neoadjuvant chemotherapy to treat breast cancer. The study is expected to be completed in the fourth quarter of 2017. NOXXON Pharma N.V.a biotechnology company whose core focus is on improving cancer treatment by targeting the tumor microenvironment, announced it had signed an agreement with the National Center for Tumor Diseases (NCT) in Heidelberg. Under this agreement, the NCT will conduct a trial evaluating NOXXON’s lead product candidate NOX-A12 in combination with Keytruda ® (pembrolizumab) in metastatic pancreatic and colorectal cancer. After a comprehensive portfolio review, MOLOGEN has presented its new Next Level strategy. The strategy focuses on developing MOLOGEN from a company driven purely by research into a strongly product and market-oriented company focused on the TLR9 product family and lead compound Lefitolimod. The primary goal is to license Lefitolimod. Accordingly, the company is focused on four ongoing clinical studies with Lefitolimod. Academic research More than 30 universities and research institutes with life sciences programs, a unique non-university research landscape encompassing renowned institutions including the Max Planck and Fraunhofer institutes, the Helmholtz Association and the Leibniz Association, as well as Europe’s largest university clinic, Charité – Universitätsmedizin Berlin, make the German capital region one of the world’s leading life sciences locations. The focal areas of biotechnology research are drug development, molecular diagnostics, and bioanalytics, regenerative medicine, proteome and genome research, and some areas of white biotechnology. The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) engages in basic biomedical research with the goal of understanding the molecular foundations of health and illness and bringing this knowledge to clinical applications in the most direct way possible. Their focus is on diagnostics and therapy as well as on preventing illnesses. Scientists at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) research key biological processes as well as the causes of illness on the molecular level, such as cancer, aging processes such as osteoporosis, and degenerative neural disorders. In addition, they develop and use highly modern technologies such as screening methods, NMR technologies, mass spectrometry, and in vivo models. Charité – Universitätsmedizin Berlin is one of Europe’s largest university clinics. Physicians and scientists research, heal, and teach here at a level matched by few facilities around the world, following a long tradition at the institution. Over half of Germany’s Nobel Prize winners for medicine and physiology come from Charité, including Emil von Behring, Robert Koch, and Paul Ehrlich. The university clinic is respected worldwide as an outstanding training center. Charité is the joint medical department of the Freie Universität Berlin and the Humboldt-Universität zu Berlin. Charité, which includes around 100 clinics and institutions structured into 17 Charité centers, is distributed across a total of four locations. With 13,200 employees, Charité generates 1.6 billion euros of total income each year, making it one of Berlin’s largest employers.

Publications in English

Publikationen auf deutsch

Clusterreport Verkehr, Mobilität und Logistik
Automotive in der Hauptstadtregion Berlin-Brandenburg
Aerospace Industrie
Biotech- und Pharmaindustrie
Forschung für die Gesundheit
Gesundheitsversorgung und Prävention
Potenzialstudie Medizintourismus Berlin-Brandenburg_2015
Clusterbroschuere Gesundheitswirtschaft
Prävention und Gesundheitsförderung
Rehabilitation in Berlin und Brandenburg
Games Industrie in der Hauptstadtregion Berlin-Brandenburg
Digitale Wirtschaft in Berlin
Fernsehen in der Hauptstadtregion Berlin-Brandenburg
Fashion in Berlin
Best Practice Wireless in der Hauptstadtregion Berlin-Brandenburg
Medien und Kreativwirtschaft in Berlin-Brandenburg
Turbomaschinen und Kraftwerkstechnik
Energienetze und -speicher in der Hauptstadtregion Berlin-Brandenburg
Kreislaufwirtschaft in Berlin
Wasserwirtschaft in Berlin
Energietechnik in der Hauptstadtregion Berlin-Brandenburg
Inkubationsprogramme in der Energiewirtschaft
Service Packages für Unternehmen in Berlin
Unternehmensservice in den Berliner Bezirken
Berlin Partner: Unser Service fuer Sie